Carmell (CTCX) Competitors $2.68 +0.12 (+4.69%) As of 06/10/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTCX vs. TLSI, SKIN, PROF, AVR, INGN, BSGM, CVRX, ELMD, RCEL, and LNSRShould you be buying Carmell stock or one of its competitors? The main competitors of Carmell include TriSalus Life Sciences (TLSI), Beauty Health (SKIN), Profound Medical (PROF), Anteris Technologies Global (AVR), Inogen (INGN), BioSig Technologies (BSGM), CVRx (CVRX), Electromed (ELMD), AVITA Medical (RCEL), and LENSAR (LNSR). These companies are all part of the "medical equipment" industry. Carmell vs. Its Competitors TriSalus Life Sciences Beauty Health Profound Medical Anteris Technologies Global Inogen BioSig Technologies CVRx Electromed AVITA Medical LENSAR TriSalus Life Sciences (NASDAQ:TLSI) and Carmell (NASDAQ:CTCX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation, dividends and community ranking. Which has better earnings and valuation, TLSI or CTCX? Carmell has lower revenue, but higher earnings than TriSalus Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTriSalus Life Sciences$32.14M6.39-$59.04M-$1.12-4.85Carmell$32.84K1,706.06-$15.44MN/AN/A Which has more volatility & risk, TLSI or CTCX? TriSalus Life Sciences has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, Carmell has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Is TLSI or CTCX more profitable? Carmell has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -206.24%. TriSalus Life Sciences' return on equity of 0.00% beat Carmell's return on equity.Company Net Margins Return on Equity Return on Assets TriSalus Life Sciences-206.24% N/A -236.83% Carmell N/A -217.50%-50.22% Do analysts recommend TLSI or CTCX? TriSalus Life Sciences currently has a consensus target price of $10.75, indicating a potential upside of 97.97%. Given TriSalus Life Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe TriSalus Life Sciences is more favorable than Carmell.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TriSalus Life Sciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Carmell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in TLSI or CTCX? TriSalus Life Sciences received 14 more outperform votes than Carmell when rated by MarketBeat users. CompanyUnderperformOutperformTriSalus Life SciencesOutperform Votes14100.00% Underperform VotesNo VotesCarmellN/AN/A Does the media refer more to TLSI or CTCX? In the previous week, TriSalus Life Sciences had 8 more articles in the media than Carmell. MarketBeat recorded 10 mentions for TriSalus Life Sciences and 2 mentions for Carmell. TriSalus Life Sciences' average media sentiment score of 1.22 beat Carmell's score of 0.00 indicating that TriSalus Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Carmell 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in TLSI or CTCX? 2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 24.2% of Carmell shares are owned by institutional investors. 27.5% of TriSalus Life Sciences shares are owned by insiders. Comparatively, 29.0% of Carmell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryTriSalus Life Sciences beats Carmell on 9 of the 16 factors compared between the two stocks. Get Carmell News Delivered to You Automatically Sign up to receive the latest news and ratings for CTCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTCX vs. The Competition Export to ExcelMetricCarmellSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.03M$4.37B$5.60B$8.61BDividend YieldN/A42.67%5.28%4.18%P/E RatioN/A29.0427.2219.97Price / Sales1,706.0670.75408.95152.58Price / CashN/A51.0838.2534.64Price / Book2.505.837.114.68Net Income-$15.44M$67.63M$3.24B$248.05M7 Day Performance-17.54%0.27%2.47%2.40%1 Month Performance1,651.63%15.22%8.66%6.14%1 Year Performance28.23%18.13%31.22%13.62% Carmell Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTCXCarmellN/A$2.68+4.7%N/A+19.9%$56.03M$32.84K0.0014News CoverageGap UpTLSITriSalus Life Sciences3.6389 of 5 stars$5.57-0.4%$10.75+93.2%-11.9%$210.57M$32.14M-2.23106Positive NewsShort Interest ↓Analyst RevisionSKINBeauty Health0.3102 of 5 stars$1.63+1.6%$1.42-12.8%-22.4%$206M$322.47M-3.891,030PROFProfound Medical2.5739 of 5 stars$6.57+14.2%$11.50+75.2%-24.0%$197.33M$11.86M-4.90150Positive NewsGap DownAVRAnteris Technologies GlobalN/A$5.32-0.9%$16.50+210.2%N/A$191.85M$2.70M0.00138Lockup ExpirationAnalyst RevisionINGNInogen4.3181 of 5 stars$6.75+1.7%$9.50+40.7%-22.1%$181.51M$339.96M-3.001,030Positive NewsBSGMBioSig Technologies2.2991 of 5 stars$6.59+4.5%$10.00+51.9%+1,325.5%$177.42M$26K0.0050Gap UpCVRXCVRx2.8876 of 5 stars$6.42+3.0%$14.50+125.9%-30.8%$167.39M$52.87M-2.39160Analyst RevisionELMDElectromed1.9872 of 5 stars$19.70-0.6%$38.00+92.9%+32.3%$164.95M$61.44M26.23160RCELAVITA Medical1.3597 of 5 stars$5.92-3.1%$16.50+178.7%-32.6%$156.50M$71.66M-2.48130News CoverageAnalyst RevisionLNSRLENSAR1.2697 of 5 stars$12.93-1.2%$15.00+16.0%+168.3%$152.46M$57.07M-8.86110 Related Companies and Tools Related Companies TLSI Alternatives SKIN Alternatives PROF Alternatives AVR Alternatives INGN Alternatives BSGM Alternatives CVRX Alternatives ELMD Alternatives RCEL Alternatives LNSR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTCX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carmell Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carmell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTCX Stock Free CTCX Stock Alerts